Antineo : Myeloma tumour model – RPMI 8226
-
RPMI 8226 cells
Human RPMI 8826 cells were isolated from the peripheral blood of a patient with a Plasmocytoma.
-
Tumour growth in vivo
The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.
The mice bearing RPMI 8226 tumours can be treated by intra-peritoneal, intra-venous, intratumoral or subcutaneous injection of the compounds. Per os administration is also possible.
Figure 1: (View PDF)
Tumour growth curve of the RPMI 8826 cells as xenograft
Mean ± SEM (n=4; take rate 100%)
-
Standard-Of-Care Drug Reponses
daratumumab 15 mg/kg qw → Response
Figure 2: (View PDF)
Effect of daratumumab treatment on RPMI 8226 tumour
growth
Mean ± SEM (n=4 per group; take rate 100%)
A RPMI 8226 model resistant to daratumumab, developed in vivo without genetic modifications, are available at Antineo (model ID RPMI 8226 daraR).